IL253570B - Pharmacy composition - Google Patents

Pharmacy composition

Info

Publication number
IL253570B
IL253570B IL253570A IL25357017A IL253570B IL 253570 B IL253570 B IL 253570B IL 253570 A IL253570 A IL 253570A IL 25357017 A IL25357017 A IL 25357017A IL 253570 B IL253570 B IL 253570B
Authority
IL
Israel
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
IL253570A
Other languages
English (en)
Hebrew (he)
Other versions
IL253570A0 (en
Original Assignee
Semnur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semnur Pharmaceuticals Inc filed Critical Semnur Pharmaceuticals Inc
Publication of IL253570A0 publication Critical patent/IL253570A0/en
Publication of IL253570B publication Critical patent/IL253570B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL253570A 2015-01-21 2017-07-19 Pharmacy composition IL253570B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562106045P 2015-01-21 2015-01-21
PCT/US2016/014165 WO2016118649A1 (en) 2015-01-21 2016-01-20 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
IL253570A0 IL253570A0 (en) 2017-09-28
IL253570B true IL253570B (en) 2020-08-31

Family

ID=55405453

Family Applications (1)

Application Number Title Priority Date Filing Date
IL253570A IL253570B (en) 2015-01-21 2017-07-19 Pharmacy composition

Country Status (13)

Country Link
US (4) US10500284B2 (enExample)
EP (2) EP3247329B3 (enExample)
JP (4) JP6829201B2 (enExample)
KR (2) KR102600792B1 (enExample)
CN (2) CN112957320A (enExample)
AU (1) AU2016209332B2 (enExample)
BR (1) BR112017015452B1 (enExample)
CA (1) CA2974657C (enExample)
ES (1) ES2877371T7 (enExample)
IL (1) IL253570B (enExample)
MX (2) MX386732B (enExample)
TW (3) TWI772659B (enExample)
WO (1) WO2016118649A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ, インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
TWI772659B (zh) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方
US11857554B2 (en) * 2015-06-02 2024-01-02 Intravital Pty Ltd. Drug delivery device with pre-assembled cartridge
EP3820479B1 (en) 2018-07-09 2026-03-11 Taiwan Liposome Co., Ltd. Methods to reduce complications of intra-articular steroid
IT201800010415A1 (it) * 2018-11-19 2020-05-19 Innate S R L Composizione iniettabile comprendente acido ialuronico e trealosio e uso della detta composizione.
CN112870155B (zh) * 2021-03-08 2023-06-30 上海昱聚科技有限公司 缓释地塞米松药物的凝胶注射剂及其制备方法和应用
JP2026502695A (ja) * 2023-01-26 2026-01-23 インシグニア・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー 変形性関節症の処置のための医薬組成物
WO2025219919A1 (en) * 2024-04-19 2025-10-23 Beam Medical Inc. Anesthetic pharmaceutical compositions, kits and uses thereof for slow release of an anesthetic agent and concurrent medical imaging of its distribution
WO2026042106A1 (en) * 2024-08-22 2026-02-26 Steriscience Specialties Private Limited Injectable formulations of dexamethasone

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) * 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
AU604236B2 (en) 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) * 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) * 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
CN101094690A (zh) * 2003-11-12 2007-12-26 阿勒根公司 用于治疗眼后节的组合物及方法
US20050186229A1 (en) * 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) * 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
WO2007070547A2 (en) * 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20070141160A1 (en) 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
CN100534434C (zh) 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠地塞米松脂肪乳制剂及其应用
WO2008057364A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Method for treating blepharitis
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
WO2009129148A2 (en) 2008-04-18 2009-10-22 Medtronic, Inc. Methods and compositions for treating intervertebral disc herniations
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
CN101683532A (zh) * 2008-09-25 2010-03-31 武汉诺安药业有限公司 含玻璃酸或其盐的眼用复方药物制剂
US20110281834A1 (en) 2008-11-10 2011-11-17 Friden Phillip M Pharmaceutical Formulations for Iontophoretic Delivery of a Corticosteroid
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) * 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
WO2013085769A1 (en) 2011-12-06 2013-06-13 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ, インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
TWI772659B (zh) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
US11020485B2 (en) 2021-06-01
KR102824858B1 (ko) 2025-06-26
US12285485B2 (en) 2025-04-29
JP6829201B2 (ja) 2021-02-10
IL253570A0 (en) 2017-09-28
TWI772659B (zh) 2022-08-01
ES2877371T3 (es) 2021-11-16
HK1245653A1 (zh) 2018-08-31
US20180185494A1 (en) 2018-07-05
US10500284B2 (en) 2019-12-10
TWI845973B (zh) 2024-06-21
EP3247329B1 (en) 2021-05-19
CA2974657C (en) 2024-02-20
AU2016209332A1 (en) 2017-09-07
JP2020073576A (ja) 2020-05-14
KR20230157534A (ko) 2023-11-16
MX2021012029A (es) 2021-10-26
MX386732B (es) 2025-03-19
BR112017015452B1 (pt) 2022-11-08
US20200197523A1 (en) 2020-06-25
AU2016209332B2 (en) 2020-10-22
EP3247329B3 (en) 2022-02-09
EP3925597A1 (en) 2021-12-22
BR112017015452A2 (pt) 2018-01-23
EP3925597B1 (en) 2026-08-19
KR20170103974A (ko) 2017-09-13
HK1243932A1 (zh) 2018-07-27
MX2017009482A (es) 2017-11-15
TWI674899B (zh) 2019-10-21
CN112957320A (zh) 2021-06-15
ES2877371T7 (es) 2022-05-24
WO2016118649A1 (en) 2016-07-28
JP7269992B2 (ja) 2023-05-09
TW201630609A (zh) 2016-09-01
JP2021183649A (ja) 2021-12-02
JP7065129B2 (ja) 2022-05-11
US20210386859A1 (en) 2021-12-16
CA2974657A1 (en) 2016-07-28
CN107205926A (zh) 2017-09-26
US20180008714A1 (en) 2018-01-11
TW202245791A (zh) 2022-12-01
JP2021143209A (ja) 2021-09-24
KR102600792B1 (ko) 2023-11-10
EP3247329A1 (en) 2017-11-29
US10117938B2 (en) 2018-11-06
CN107205926B (zh) 2021-03-05
TW202005652A (zh) 2020-02-01
JP2018502872A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
PL4233846T3 (pl) Formulacje farmaceutyczne
IL256491A (en) Pharmaceutical formulations
IL271226A (en) medical preparation
AU2016218074B2 (en) Pharmaceutical formulation
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL253570A0 (en) Pharmacy composition
IL266537A (en) pharmaceutical preparation
GB201521462D0 (en) Pharmaceutical composition
ZA201707094B (en) Pharmaceutical formulations
PL3389633T3 (pl) Kompozycje farmaceutyczne zawierające pochodną fenyloaminopirymidyny
ZA201807851B (en) Pharmaceutical formulation
GB201506755D0 (en) Novel pharmaceutical formulation
GB201515310D0 (en) Pharmaceutical composition
PL3601277T3 (pl) Preparat farmaceutyczny
IL275144A (en) Pharmacy preparation
GB201520862D0 (en) Pharmaceutical composition
GB201417589D0 (en) Pharmaceutical Formulations
GB201511246D0 (en) Pharmaceutical formulation
GB201719873D0 (en) Pharmaceutical formulation
GB201604545D0 (en) Novel pharmaceutical formulation
GB201521456D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed